Aker october 2014 speaking presentation

October 2014

2

Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Akers Biosciences, Inc. (ABI or the Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. The Company disclaims any intent or obligation to update these forward-looking statements.

COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR

Introduction

• Bringing diagnostics to the point-of-care • Multiple core products with blockbuster potential • Faster, better diagnostics which take costs out of the

healthcare system

3 COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR

4


Products Selling NOW

5

• Only FDA cleared test to detect heparin allergies; competes with expensive, slow turn-around laboratory tests

• 25 million patients in US and EU receive heparin annually

• 4 million tests performed annually in laboratories in US which could be replaced with

PIFA


STAT Point-of-Care

6

Only combined rapid test for Total, HDL and LDL cholesterol


7 COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR

Research & Discovery

Clinical Development

Commercial Development

Launch & Market Entry

Pipeline products

Dengue Fever

Troponin 1

Chlamydia

Malaria

Diabetic Ketoacidosis

COPD

Lung Cancer

Asthma

8

Developing the world’s first rapid diagnostic assays for Lung Cancer Asthma & COPD through breath

• LUNG CANCER: > 1.6 million people diagnosed each year • ASTHMA: Up to 15% of a country’s population may have Asthma • COPD: 1 billion smokers at risk for COPD


9

Improving how diabetics manage Ketoacidosis

• Type 1, and some Type 2, diabetics are at risk for developing ketoacidosis (blood acid build-up)

• 3 million type 1 diabetics in US • Reduces healthcare costs by decreasing the need for hospital visits and

expensive lab testing


10

• Design and Development Agreement with Konica Minolta • Will be First 5 minute POC test to detect marker of heart attack

• Nearly 1 million heart attacks each year in US


Point-of-Care PIFA Troponin I

Improving the way Myocardial Infarction is Diagnosed

11

Milestones


• Enhance sales and marketing capabilities

• Expand US distribution of PIFA PF4 products • Expand international distribution of PIFA PF4 products: China, India, EU, S. America • Create US distribution channels for Tri-Cholesterol “Check”, METRON and VIVO

worldwide • Product launches/clinical trials - Breath Ketone “Check” - PIFA Chlamydia Breath Asthma “Check” Breath Lung Cancer “Check” Breath COPD “Check”

• New healthcare environment demands cost-containment

• Multiple products with blockbuster potential already selling

• Substantial new product pipeline with mass market potential

12

Summary


Appendix

14

Profit and Loss


Six Months Fiscal Year Ended Jun 30 Ending Dec 31

2014 2013 2012

Revenue $2,527,076

$3,577,851

$1,564,101

Gross Profit 1,781,344

1,664,007

556,150

Administrative Expenses 1,670,728

1,524,626

1,493,707

Sales & Marketing Expenses 607,707

684,720

638,732

Research & Development Expenses 502,489

1,006,800

900,380

Operating Profit (1,128,867)

(1,526,773)

(2,725,228)

Net Profit (1,090,595)

(1,526,773)

(2,557,820)

15

Balance Sheet Overview


As of

Jun 30, 2014 Dec 31, 2013

Total Assets 17,773,670 6,075,622

Total Liabilities

1,110,437

1,953,388

Total Equity

16,663,233

4,122,234

16

Capitalization Structure


June 30, 2014 Shares

Common Shares 4,894,837

Directors & Officers Options – Exercise Price of $5.50 115,000

Key Employee Options – Exercise Price of $3.98 60,000

Warrants – Exercise Price of $71.76 1,989

Total – Fully Diluted 5,071,826

17

Experienced, Focused Management and Board

Raymond F. Akers, Jr. Ph.D. Founder, Executive Chairman of the Board (Director) • 30+ years in medical diagnostics; founded ABI in 1989 • Invented most of ABI’s products and technologies; numerous patents • Ph.D. in Neurochemistry, Northwestern University


Edwin C. Hendrick Executive Vice President, Sales and Marketing • 25 year career in healthcare leading the commercial aspects of

diagnostic and healthcare services companies ranging in size from $10 million to $1 billion in revenues; joined ABI in 2014

• Most recent engagements include executive positions with PLUS Diagnostics , US Labs and Ventana Medical Systems

Patrice Laterra McMorrow Vice President, Marketing • 20+ years in sales and marketing in diagnostics, pharmaceutical,

and ophthalmic industries; joined ABI in 2004 • Competencies: new product launches, sales operations, and

distribution management

Officers & Key Management Team

Gary M. Rauch Vice President, Finance • 35+ years in accounting, information systems, and operations

consulting, joined ABI in 2010 • Engagements in healthcare, manufacturing and distribution

Non-Executive Directors

Gavin E.D. Moran • Extensive experience in trading, finance and marketing • Trading roles at Shell International, Trafigura Ltd, and since

April 2010, beneficial shareholder at Sono International Ltd

Thomas J. Knox • Expertise in health care and finance • Former CEO of United Healthcare of Pennsylvania; Former

Chairman of the Board and Chief Executive Officer of Fidelity Insurance Group, Inc.

• Currently Chief Executive Officer of Knox Consulting Group, Chairman of ORB Automotive Corporation, Ltd.

Brandon T. Knox • Experience incorporate finance and financial management • Currently wealth advisor at Raymond James

Nicolas Daurel Vice-President, Sales and Marketing, EMEA • 20+ years experience in international sales • Held similar positions with Trinity Biotech plc, Diagnositica

Stago, SA, Roche Diagnostics

Date post:	23-Jun-2015
Category:	Investor Relations
Upload:	redchip-companies-inc
View:	58 times
Download:	0 times

Aker october 2014 speaking presentation

Investor Relations